Search results
10 lip 2021 · A comprehensive range of investigations and molecular typing are essential to accurately predict prognosis, which can vary from spontaneous resolution to life-threatening disseminated disease. Targeted therapies with BRAF or MEK inhibitors have revolutionised salvage treatment.
Langerhans cell histiocytosis is a rare clonal disease characterized by the proliferation of CD1a-positive immature dendritic cells. The purpose of this article was to present an updated review of recent advances in the pathogenesis, clinical features, imaging and treatment of this disease.
1 mar 1987 · Several suggestions are made for the optimal design and performance of clinical studies aimed at evaluating potentially new therapies, including the proper identification and use of controls. In addition, a staging system is described, and a comprehensive scoring system is given.
1 wrz 2021 · Familiarity with principles of evaluation and treatment both shared among and distinct to each of these 3 diseases is critical for effective management. Refractory or disabling neurohistiocytic involvement should prompt the consideration for use of targeted kinase inhibitor therapies.
16 maj 2021 · We present the recent advances that molecular and genomic investigations have brought to the pathogenesis and therapy of the histiocytoses, and we review the management strategies of these 3 entities.
1 mar 1987 · These techniques have included changes in the level of cyclic nucleotides following treatment with histamine,74 as well as binding of cells to histamine-coated sepharose beads6 or erythrocytes.75 More recently, we have used biochemical techniques to identify specific and separate distinct Ηχ and H2 receptors on lymphoid cells.68 Lymphocyte ΗÏ...
Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome), Schüller-Christian syndrome and multifocal eosinophilic granuloma
